Seralutinib
Phase 3Active 0 views this week 0 watching💤 Quiet
Interest: 34/100
34
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Pulmonary Arterial Hypertension
Conditions
Pulmonary Arterial Hypertension
Trial Timeline
Sep 3, 2024 → Dec 1, 2026
NCT ID
NCT06274801About Seralutinib
Seralutinib is a phase 3 stage product being developed by Gossamer Bio for Pulmonary Arterial Hypertension. The current trial status is active. This product is registered under clinical trial identifier NCT06274801. Target conditions include Pulmonary Arterial Hypertension.
What happened to similar drugs?
20 of 20 similar drugs in Pulmonary Arterial Hypertension were approved
Approved (20) Terminated (1) Active (0)
✅Arformoterol Tartrate Inhalation Solution + Arformoterol Tartrate Inhalation Solution + PlaceboSumitomo PharmaApproved
Hype Score Breakdown
Clinical
17
Activity
12
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06274801 | Phase 3 | Active |
Competing Products
20 competing products in Pulmonary Arterial Hypertension